CJC-1295 & Ipamorelin vs Dulaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295 & Ipamorelin
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic) work synergistically to stimulate natural growth hormone release with potentially greater effects than either peptide alone.
Full details →Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 & Ipamorelin | Dulaglutide |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors to sustain GH signaling and extend the half-life of growth hormone release. Ipamorelin triggers strong GH pulses by binding to ghrelin receptors. Together, they create both sustained and pulsatile GH release patterns that more closely mimic natural physiology. | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. |
| Typical Dosage | CJC-1295 (no DAC/Mod GRF 1-29): 100-300mcg combined with Ipamorelin 200-300mcg, administered 1-3 times daily. Best results when administered fasted or before sleep. | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. |
| Administration | Subcutaneous injection. Often administered before bedtime to enhance natural nighttime GH release, or in the morning fasted. The combination is typically pre-mixed or injected simultaneously. | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. |
| Side Effects | Water retention, tingling in extremities, mild headaches, lightheadedness, or increased hunger. Generally well-tolerated with minimal effect on cortisol or prolactin. | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. |
| Best For |
What They Have in Common
Both CJC-1295 & Ipamorelin and Dulaglutide are commonly used for: